Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10104076 | 0.96 | CHRM5 (0.56) | CHRM5ADRA2CACHEHRH3MAPT | |
| SCHEMBL15242459 | 0.94 | CHRM5 (0.59) | CHRM5ADRA2CACHEHRH3MAPT | |
| SCHEMBL22520769 | 0.91 | CHRM5 (0.43) | CHRM5ADRA2CACHEHRH3TLR9 | |
| SCHEMBL14453909 | 0.89 | CHRM5 (0.41) | CHRM5ADRA2CACHEHRH3TLR9 | |
| SCHEMBL24233173 | 0.88 | ACHE (0.44) | CHRM5ADRA2CACHEHRH3TLR9 | |
| SCHEMBL21477202 | 0.87 | CHRM5 (0.39) | CHRM5ADRA2CACHEHRH3SIGMAR1 | |
| SCHEMBL15242464 | 0.84 | CHRM5 (0.47) | CHRM5ADRA2CACHEHRH3MAPT | |
| SCHEMBL23205756 | 0.84 | CHRM5 (0.47) | CHRM5ADRA2CACHEHRH3MAPT | |
| SCHEMBL23484949 | 0.84 | ACHE (0.60) | CHRM5ADRA2CACHEHRH3TLR9 | |
| SCHEMBL13300929 | 0.84 | HRH3 (0.46) | CHRM5ADRA2CACHEHRH3TLR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020119739-A1 | 2-AMINOPYRIMIDINE COMPOUND AND APPLICATION THEREFOR | 暨南大学 | 2020-06-18 | — | — | WO | disclosed |
| US-7531532-B2 | Hepatocyte growth factor receptor inhibitors; Antitumor agents, anticarcinogenic agents, angiogenesis inhibitors; pyrimidine derivatives like Pyrrolidine-1-carboxylic acid [6-(2-fluoro-4-{3-[2-(4-fluorophenyl)acetyl]thioureido}phenoxy)pyrimidin-4-yl]amide | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-05-12 | — | — | US | disclosed |
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | HGF, MET, FLT1 | CHRM5 2795/4885ADRA2C 2788/4885ACHE 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.